This histogram enumerates side effects from a completed 2016 Phase 3 trial (NCT02008565) in the Loperamide - Education Only ARM group. Side effects include: Constipation with 38%, Urinary tract infection with 10%, Fall with 8%, Abdominal pain with 8%, Diarrhoea with 7%.
1 Treatment Group
1 of 1
85 Total Participants · 1 Treatment Group
Primary Treatment: Usual Care · No Placebo Group · N/A
Group 2Experimental Group · 3 Interventions: Usual Care, Dietary Counseling, Exercise Training · Intervention Types: Other, Behavioral, Behavioral
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 3
Screening: ~3 weeks
Reporting: 1 year
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,678 Total Patients Enrolled
6 Trials studying Heart Failure
232 Patients Enrolled for Heart Failure
Karen Basen-Engquist, PhDPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
2,526 Total Patients Enrolled
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You are living in the Houston area (Harris county or a contiguous county), or planning to stay in the area for at least the next 16 weeks.
You have received chemotherapy that contributed to the development of heart failure.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.